GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Pharmaceutical

GNI Group

Ying Luo

Thomas Eastling

Kan-Ichiro Suzuki

Hideaki Sashiwa

Kanako Kikuchi

Ryosuke Matsui

Sekitani Kazuki

Leadership Team

GNI Group

Org chart

Board & advisors

Teams

Leadership Team

Offices

Similar companies